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Abstract
Background: Substantial resources and patient commitment are required to successfully scale-up antiretroviral therapy
(ART) and provide appropriate HIV management in resource-limited settings. We used pharmacy refill records to evaluate
risk factors for loss to follow-up (LTFU) and non-adherence to ART in a large treatment cohort in Nigeria.
Methods and Findings: We reviewed clinic records of adult patients initiating ART between March 2005 and July 2006 at
five health facilities. Patients were classified as LTFU if they did not return .60 days from their expected visit. Pharmacy refill
rates were calculated and used to assess non-adherence. We identified risk factors associated with LTFU and non-adherence
using Cox and Generalized Estimating Equation (GEE) regressions, respectively. Of 5,760 patients initiating ART, 26% were
LTFU. Female gender (p,0.001), post-secondary education (p=0.03), and initiating treatment with zidovudine-containing
(p=0.004) or tenofovir-containing (p=0.05) regimens were associated with decreased risk of LTFU, while patients with only
primary education (p=0.02) and those with baseline CD4 counts (cell/ml
3) .350 and ,100 were at a higher risk of LTFU
compared to patients with baseline CD4 counts of 100–200. The adjusted GEE analysis showed that patients aged ,35 years
(p=0.005), who traveled for .2 hours to the clinic (p=0.03), had total ART duration of .6 months (p,0.001), and CD4
counts .200 at ART initiation were at a higher risk of non-adherence. Patients who disclosed their HIV status to spouse/
family (p=0.01) and were treated with tenofovir-containing regimens (p#0.001) were more likely to be adherent.
Conclusions: These findings formed the basis for implementing multiple pre-treatment visit preparation that promote
disclosure and active community outreaching to support retention and adherence. Expansion of treatment access points of
care to communities to diminish travel time may have a positive impact on adherence.
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Introduction
Nigeria is home to the second highest number of people living
with HIV in the world and the highest in West Africa, with an
estimated 2.6 million infected at the end of 2007[1]. Substantial
resources and patient commitment are both required to success-
fully scale-up antiretroviral therapy (ART), minimize loss to
follow-up (LTFU), and ensure optimal adherence in this setting.
Although substantial rates of LTFU have been shown in ART
programs in resource limited settings[2,3,4,5], ranging from
16%[6] to as high as 40% after 2 years[4], risk factors and
patient-level and program-level characteristics of LTFU in these
settings have received little attention because of limited access to
longitudinal patient-level data. This is further compounded by the
lack of mandate by donor agencies to report program metrics on
patients’ retention and patients’ adherence to treatment[7].
Several studies in Africa have shown a high level of medication
adherence[8] demonstrating that scale-up of ART in resource-
limited settings can achieve durable immunologic and clinical
outcomes. The majority of these findings were based on small
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10584study populations[2,9,10], supervised cohort[11], and/or patient-
reported adherence level[10,12]. Subsequent reports have raised
concern regarding sub-optimal adherence when assessed by
pill counts, pharmacy records, or electronic monitoring
[13,14,15,16,17].
Lack of adherence to antiretroviral medications and attrition
from health services contribute to poorer health outcomes and
waste limited resources. Identifying patient characteristics that are
associated with these outcomes could be used for making evidence-
informed decisions to improve patient care and programmatic
outcomes. In this paper, we describe risk factors for LTFU and
non-adherence to antiretrovirals in a large antiretroviral therapy
program in Nigeria.
Methods
In 2005, the AIDS Care and Treatment in Nigeria (ACTION)
project was created as a joint initiative between the Institute of
Human Virology of the University of Maryland School of
Medicine, the Institute of Human Virology Nigeria, the Nigerian
Federal Ministry of Health, and local partner treatment facilities.
The goals of ACTION are to implement a multidisciplinary
program of primary HIV prevention, and HIV care and support
that employs an evidence-based approach using robust strategic
information systems to monitor performance and evaluate quality
in order to continually improve program sustainability.
This is a retrospective analysis of existing data and was
determined to be exempt from oversight after review by the
National Health Research Ethics Committee of Nigeria and the
University of Maryland Baltimore Institutional Review Board.
Patients were included in the analysis if they were non-pregnant
treatment-naive adults initiating first-line ART between March
2005 and July 2006 at five tertiary hospitals in Nigeria. Among the
first in Nigeria to provide large-scale ART access through support
from PEPFAR, the local partner treatment facilities included were
the University of Abuja Teaching Hospital (UATH), the
University of Benin Teaching Hospital (UBTH), the Aminu Kano
Teaching Hospital (AKTH), the Nnamdi Azikwe University
Teaching Hospital (NAUTH), and the University of Calabar
Teaching Hospital (UCTH). All WHO clinical stage 4 patients,
stage 3 patients with a CD4 cell count ,350 cells/ul, and stage 1
and stage 2 patients with a CD4 cell count ,200 ul were eligible
for ART in accordance with the Nigerian National Guide-
lines[18]. Patients were followed from the time of ART initiation
until either LTFU or to October 31, 2006 to allow for a minimum
of 90 days in the interval of analysis.
Clinical procedures and Data collection
At clinic enrollment, patients underwent a history and physical
examination and were interviewed by staff in order to complete an
intake record which included demographic data. During this
period, adherence counseling was routinely provided to patients,
but a regimented intensive HIV treatment preparation program
was not offered as part of routine clinical care. Six first-line
treatment regimens were prescribed: (stavudine [d4T] + lamivu-
dine [3TC] + nevirapine [NVP]/efavirenz[EFV]), (zidovudine
[ZDV] + 3TC + NVP/EFV), and (tenofovir [TDF] + 3TC +
NVP/EFV). Although physicians were trained to prescribe ZDV
as a first choice, with TDF used if anemia was present and utilize
EFV with concomitant anti-tuberculosis treatment with exception
for child-bearing age women, choice of regimen was at the
discretion of the physician. Patients were scheduled for a follow-up
visit one month after ART was first dispensed and then every two
or three months at the discretion of the physician. A sufficient
supply of ART was dispensed to last until the next scheduled visit.
At each follow-up visit, patients underwent a history and physical
and any side effects reported were recorded by the physician on a
clinical encounter form. A pharmacy order form, which includes
the date ART was dispensed, the formulations dispensed, and the
quantity of each formulation dispensed, was completed by the
physician at each visit and presented to the pharmacist for ART
dispensing.
Form data were entered in real-time into the CAREWare
health management information system. Originally developed for
the US domestic HIV treatment and care program under the
Ryan White CARE Act, the system has been adapted by the US
Department of Health and Human Services Health Resources and
Service Administration for resource-limited setting through
PEPFAR and was deployed by the ACTION project.
Statistical Analysis
For the LTFU analysis, time-to-event analytical method was
used. Patients were considered LTFU when they did not return to
the clinic more than 60 days from their last expected visit. The risk
of LTFU was determined using Cox proportional hazard
regression with ART initiation as time zero. The proportional
hazards assumption was assessed with log-log plots and regression
of the Schoenfeld residuals[19]; the goodness of fit was assessed by
log-likelihood test.
For the non-adherence to ARV analysis, pharmacy dispensing
records over the duration of ARV therapy for each patient were
reviewed. Each patient was required to have been receiving ART
for a minimum of 90 days to be included in the analysis. Days of
medication dispensed between visits was calculated. A pharmacy
refill adherence rate (Rx) was then calculated (days of medication
dispensed/days between visits multiplied by 100). For each visit
interval when the Rx is less than 95% (i.e. an episode of
Rx,95%), a binary outcome of 1 was designated (i.e. a value of 0
denoted a visit where Rx $95%). Given the longitudinal nature of
the outcome, the risk factor analysis for Rx,95% within the first
12 months of initiating ART were modeled as the odds of having
Rx,95% at any given visit using Generalized Estimating
Equation[20,21] accounting for correlation between repeated
measurements using a covariance structure of unequally spaced
data. The quasi-likelihood information criterion (QIC) statistics
was used to evaluate fit[22]. In addition to QIC, goodness of
model fit was evaluated using Horton et al.9s goodness-of-fit for
logistic regression estimated by GEE[23].
In both of these primary regression analyses of LTFU and non-
adherence to ARV, potential covariates were first examined in
unadjusted models. Factors associated at the p,0.05 level with the
outcome and known risk factors for LTFU and non-adherence
regardless of their level of significance were then evaluated in
multivariate models. To control for confounding, variables that
altered any significant relative hazards or odds ratios by $20%
were retained. To account for missing data that may have not
occurred at random, multiple imputations for missing data were
performed using Markov chain Monte Carlo method (SAS Proc
MI). The analyses of the complete-data obtained through the
imputation did not change the results; therefore, only the primary
regression results are shown.
In order to model the effect of time since ART initiation as a
continuous risk factor on the outcome of Rx,95%, we fitted a
cubic polynomial model using the GEE method to obtain the
predicted values of the proportion of individuals with the outcome
from the associated b coefficients. Similar to the procedure used in
the multivariate analyses above, the model with the smallest QIC
value was chosen as the best model of time since ART initiation.
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Station, TX) for the LTFU analysis and SAS 9.2 (Cary, NC) for
the GEE analysis.
Results
Description of Study Population
The study population included 5,760 patients; 2,385 (59%) were
female and the median age at time of enrollment was 35 years
(25
th–75
th percentile: 29–41 years) – Table 1. The median CD4
absolute count at ART initiation was 121 cells/mm
3 with 76% of
the patients having had CD4#200 cells/mm
3. The majority of the
patients (51%) lived within 1 hour of travel time to the clinic. At
the time of this analysis, the median time on ART was 215 days
(25
th–75
th percentile: 110–361 days) with 44% of patients on ART
for less than or equal to 6 months, 32% on ART between 6 and 12
months, and 24% on ART for between 12 and 18 months. There
were a total of 44,571 person-months of follow-up. The majority of
the patients were initiated on zidovudine-containing or stavudine-
containing first-line regimens (46% and 41%, respectively). The
patient volume was highest at the University of Abuja Teaching
Hospital (n=1,829 patients) and lowest at the University of
Calabar Teaching Hospital (n=398 patients).
Risk Factors of Loss to Follow-up
During the follow-up period, 1494 (25.9%) patients became
LTFU (Figure 1). Cumulative incidence of LTFU was 22.9% at 6
months and 25.3% at 12 months. Of 1494 patients identified as
lost, 654 (43.8%) patients never returned for further visits after the
first clinic visit when ARVs were dispensed. Of 840 patients who
were lost later in the course of follow-up, 577 (68.7%)were lost in
the first90 days after ART initiation. LTFU was highest at the
Nnamdi Azikwe University Teaching Hospital (32.5%) and lowest
at the University of Benin Teaching Hospital (22.0%).
The characteristics associated with LTFU are shown in
Table 2. Female patients were less likely to become LTFU
(HR=0.75, 95%CI: 0.67–0.82). Patients with post-secondary
education (HR=0.80, 95%CI: 0.65–0.99) or other unspecified
education (HR=0.61, 95%CI: 0.41–0.93) were less likely to
become LTFU compared to individuals with no primary or some
primary education. Patients in the highest CD4 cells count
category (.350 cells/mm
3) and those in the lowest category
(,100 cells/mm
3) at ART initiation had higher risk of LTFU
(HR=1.47 and HR=1.41, respectively) relative to patients with
CD4 between 100 and 200 cells/mm
3. Use of a ZDV-containing
first-line regimen was associated with decreased risk of LTFU
compared with a d4T-containing regimen (HR0.85, 95%CI:
0.76–0.95). The findings, specifically the increased risk of LTFU
associated with being male, CD4 at initiation of ART ,100 and
.350, and with d4T-containing first-line regimen, remain
significant when the analyses were stratified by site (data not
shown). There was no difference in LTFU risk between EFV-
containing and NVP-containing regimens (26.2% vs. 25.9%,
p=0.84). In the adjusted Cox Regression analysis of 4,177 (72.5%)
patients with complete data variables, risk of LTFU remained
associated with gender, educational level, CD4 at the time of ART
initiation and types of first-line regimen. After adjusting for these
covariates, younger age at clinic enrollment was associated with
increased risk of LTFU.
Risk Factors of Non-Adherence to Antiretrovirals
For the analysis of pharmacy refill rates, 4529 patients who
returned for further visits beyond 90 days of ART initiation were
included. Of these, 3362 (74.2%) had a pharmacy refill rate ,95%
at any time during follow-up. A total of 1747 (38.5%) had a
summary pharmacy refill at the last visit ,95%; of which 15.8%
had Rx,50%, 33.6% with Rx of 50–79%, and 50.6% with Rx of
80–95%. In the bivariate analyses of those characteristics
associated with pharmacy refill rate ,95% (Table 3), younger
age groups (vs. patients over 45 years of age), Quranic education
(vs. having had none or some primary school), unemployment (vs.
being employed), and a CD4 count of 200 or more at time of ART
initiation were associated with increased odds of Rx,95%.
Having disclosed HIV status to either spouse or family members
was associated with decreased odds of Rx,95% (OR=0.85,
95CI: 0.76–0.94) compared to those who did not disclose to
anyone. Patients initiated on a ZDV-containing or TDF-
containing first-line regimen were less likely to have Rx,95%
compared to patients initiated on a D4T-based regimen. There
was no difference in the risk of Rx,95% between EFV-containing
and NVP-containing regimens (data not shown).
In the multivariate GEE regression which included 3,135
(70.4%) patients with complete data and adjusting for ART
duration, decreased odds of Rx,95% remained associated with
TDF-containing regimen (OR=0.73) and disclosure of HIV status
to spouse or family member (OR=0.85). Compared to patients
with CD4 cell counts between 100 and 200, patients with CD4
above 200 were at increased odds of Rx,95%; OR=1.18
(95%CI: 1.06–1.32) for patients with CD4 cell counts between 200
and 350 and OR=1.25 (95%CI: 1.05–1.49) for patients with CD4
cell counts greater than 350. There was no difference in Rx,95%
between patients with CD4,100 and those with CD4 between
100 and 200 cells/mm
3 (OR=0.98, p=0.66). Longer travel time
to the clinic (.2 hours) was associated with increased odds of
Rx,95% (OR=1.11; 95%CI: 1.01–1.23). Increased odds of
Rx,95% was also associated with increasing time on ART.
In the regression model where time since ART initiation was
modeled as a continuous risk factor, the best fitting model included
a cubic polynomial model for time. Modeled probabilities of
Rx,95% across each time-points and 95% confidence intervals
for the final best-fitting model are shown in Figure 2. The risk of
non-adherence was highest in the first 6 months after ART
initiation with the proportion of patients having Rx,95% that
ranges from 28% at 3 months to 26% at 6 months.
Discussion
In a large antiretroviral therapy program in Nigeria, approx-
imately 1 in 4 patients were LTFU between March 2005 and July
2006; this is very similar to findings from other HIV treatment
programs in sub-Saharan Africa[2,4]. In our analysis, increased
risk of LTFU was associated with being male, younger age, having
CD4 level at ART initiation below 100, and treatment with a d4T-
containing first-line regimen. These risk associations did not differ
between patients who discontinued care after one visit and patients
who returned after one visit but were eventually lost. Increased risk
of non-adherence was associated with younger age, having CD4
level at ART initiation below 200, and long travel time to the
clinic while better adherence was associated with disclosure of
HIV status to family members and first-line treatment with TDF-
containing regimen.
The finding that a higher proportion of women initiated on
ART remained in follow-up care in this cohort mirrors findings
from other treatment cohorts in Africa[4] and may reflect gender-
differences in health-seeking behaviors which has been shown to
affect retention in care in other resource-limited countries[24,25].
For HIV treatment programs to be effective in optimizing
retention, strategies are needed to effectively engage and support
Retention and Adherence to ART
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which may impact LTFU, such as alcohol use, were not assessed in
this study.
Although the majority of the patients had a CD4 level within
the range of requiring ART according to the National and WHO
guidelines[26], higher LTFU was observed for both patients whose
CD4 level was low (less than 100) and whose CD4 level was high
(above 350). The bimodal relationship suggests that the risk
associated with higher CD4 group may be due to patients who
considered themselves or felt ‘‘healthy’’ and need not return for
care while the risk associated with lower CD4 is suggestive of
patients who were too sick to engage and continue on care, or who
Table 1. Characteristics of the Study Population (N=5760).
Characteristics Number (%)
Gender Female 3375 (59)
Male 2385 (41)
Age (years) #25 683 (12)
25–30 1262 (22)
31–35 1246 (22)
35–40 1071 (19)
41–45 850 (15)
46+ 648 (11)
Health Facilities University of Abuja Teaching Hospital 1829 (32)
University of Benin Teaching Hospital 1140 (20)
Aminu Kano Teaching Hospital 989 (17)
Nnmadi Azikwe University Teaching Hospital 1404 (24)
University of Calabar Teaching Hospital 398 (7)
Educational Level Post-Secondary 1239 (22)
Completed Secondary 2049 (37)
Completed Primary 1263 (23)
Quranic education 260 (5)
None or some Primary 531 (9)
Others 163 (3)
(Missing) 255
Marital Status Currently Married 3134 (55)
Currently Not Married 2596 (45)
(Missing) 30
Employment Status Student or Unemployed 1146 (22)
Other/Retired 2224 (42)
Employed 1942 (37)
(Missing) 448
Time to Travel to the ART Center #1 Hour 2862 (51)
.1–2 Hours 1533 (27)
.2 Hours 1196 (21)
(Missing) 169
CD4 Absolute Count at Initiation of ART Median (Interquartile Range) 121(141)
.350 cells/mL
3 251 (5)
201–350 cells/mL
3 858 (19)
100–200 cells/mL
3 1567 (34)
,100 cells/mL
3 1954 (42)
(Missing) 1130
First Line ART Regimen Prescribed at Baseline ZDV/3TC/NVP or EFV 2669 (46)
TDF/3TC/NVP or EFV 731 (13)
d4T/3TC/NVP or EFV 2360 (41)
ART Duration #6 Months 2529 (44)
.6a n d,12 Months 1826 (32)
12–18 Months 1405 (24)
doi:10.1371/journal.pone.0010584.t001
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treatment can be attributable to death[27,28,29,30]. Incomplete
tracking of mortality is a major challenge in the context of ART
scale-up in settings such as this.
Nearly half of patients LTFU never returned after receiving
their first prescription of ARVs. This figure is much larger than
previously reported across different ART programs in Africa[28].
Comparing these ‘‘early’’ LTFU to patients who were subse-
quently lost showed that they were more likely to have CD4 below
100. While no other differences were observed, physicians in our
program do preferentially placed sicker patients on a TDF-
containing regimen. These data are based upon very early
program implementation. At a time of ambitious treatment goals
for PEPFAR, it is likely that inadequate resources and training
were focused on treatment preparation, and implementation of
ART services stressed a weak health service delivery system. Better
treatment preparation was implemented in response to these
findings. While there is now a national policy of free ART services
at public facilities in Nigeria, there was not a national policy at the
time regarding institutional patient charges for ART services.
There was not a national ART registration system which would
detect the same patient receiving services at multiple care sites.
There were alternative care sites with different charging policies
near the study sites at the time. Thus, some patient migration to
other ART care sites cannot be excluded.
In the analysis of the impact of various first-line regimens,
patients initiated on a stavudine-containing first-line regimen had
higher risk of LTFU compared to other regimens containing either
zidovudine or tenofovir. Stavudine has been shown to be
associated with peripheral neuropathy[31,32], lactic acidio-
sis[33,34], and lipoatrophy[35,36], and other metabolic compli-
cations[37] Although data on side effects of ART medications
were infrequently recorded or reported by patients in this
program, other studies have found that side effects can be
associated with LTFU[6]. Stavudine-containing regimens are no
longer recommended in resource-rich countries because of toxicity
and side effects but are still widely used in Nigeria (,20% of all
first-line regimens prescribed in 2008 and 2009) and other
resource-limited countries because of availability supplied by
donors. While we did not observe a secular trend in regimen
choices of physicians or differences in regimen choice by site, it is
possible that health care providers who were more likely to
prescribe stavudine may also be less competent with patient
education and adherence support. Additional studies are needed
to evaluate the long-term patient-level effects and programmatic
outcomes related to various first line ART options.
At the end of the analysis time, more than one third of the
cohort had an overall Rx,95%. There was a concordance
between the proportion of patients with at least one visit interval
with Rx,95% (i.e. an episodic Rx,95%) and the proportion of
patients with an overall summary Rx,95%, suggesting that once
patients demonstrate poor adherence in the course of follow-up,
the behavior is likely to continue and intensive adherence support
should be initiated immediately for this group of patients. The vast
majority of episodes of adherence ,95% were simply due to the
patient not returning to the health care facility for pharmacy refill
in a timely matter. Periodic discontinuation ($48 hours) of a non-
nucleoside-based ART regimen is particularly concerning for the
development of resistance due to the long half-life of these
agents[38]. The risk of non-adherence observed to be highest in
the first 6 months after ART initiation suggests that limited
adherence support resources should be focused on patients early in
their treatment course.
Good adherence was associated with disclosure of HIV status to
either spouse or family member and with a tenofovir-containing
first-line regimen. The protective effect of disclosure on non-
adherence is the first finding from a large treatment program in
Nigeria and speaks to the importance of stigma as a barrier to
effective life-long treatment adherence as also reported from South
Africa[10], Uganda[39], Botswana[40], and Zambia [41]. Because
disclosure to family members is imperative to ensure their support,
identifying tools or resources that can minimize the possible risks
and maximize the potential benefits of disclosure should be useful
in improving the care of persons living with HIV/AIDS. In
addition to counseling on disclosure, engaging the community in
HIV/AIDS care could potentially create an environment that
reduces stigma and encourages disclosure to family members[42].
While our program did not collect information on religion,
interestingly, patients with Q’uranic education were at increased
risk of being non-adherent. Studies on understanding the cultural
context of health care maintenance and adapting HIV treatment
and care services to local customs are important for ensuring
optimal clinical outcomes in various patient populations. This
finding also underscores the importance of religious organizations
and community leaders in further supporting people living with
HIV/AIDS.
Patients who spent considerable time traveling to the treatment
facilities were at increased risk of non-adherence. Although the
number of treatment facilities in Nigeria continue to increase,
patients may continue avoid accessing care from facilities within
their communities because of stigma. As a result, scale up of
treatment facilities must be coupled with support from the
communities. Beyond the standard and simple public health
Figure 1. Study Population of Patients Initiating ART between
March 2005 and July 2006.
doi:10.1371/journal.pone.0010584.g001
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ACTION project has initiated a treatment support structure with
emphasis on multiple visit pre-treatment preparation, promotion
of disclosure, and treatment companions. The ACTION project is
also implementing different models of comprehensive care delivery
such as task-shifting, expanding development of ART points of
service at the local primary health center level, home-based
care[43], treatment companions[44], more extensive and targeted
counseling, and frequent visits and monitoring by health care
workers[45,46] in order to provide structural support for
adherence and retention.
Our findings should be interpreted in light of several caveats.
First, the retrieved data were based on a clinical cohort rather than
a ‘‘classical’’ structured cohort that resulted in a variable interval
of follow-up time for patients. We accounted for these variations in
the analysis using the GEE approach[20]. Additional analyses will
be necessary to examine the influence of these risk factors beyond
the first 12 months of ART initiation. Second, the data on side
effects and mortality, which could further help explain interesting
findings, were incomplete because of logistical challenges in this
setting. Third, because viral load measurements were not routinely
performed, we were not able to characterize patients’ virologic
response to ART. Lastly, pharmacy refill records were used as a
proxy for level of adherence to ART because this was deemed to
be the most objective approach for retrospective analysis in this
cohort. Structured adherence self-report measures were utilized as
a part of routine care, but we found that many patients with poor
pharmacy refill rates self-reported excellent adherence[47].
Although pharmacy refill data does not measure medication-
taking behavior, it is considered to be a more objective measure
Table 2. Cox Regression Analyses of Characteristics Associated with Loss to Follow-Up (LTFU) Among Treatment-Naı ¨ve Adult
Nigerian Patients.
Total LTFU, n=1494, (26%) Unadjusted Adjusted
b
N
a n % HR (95% CI) P-value HR (95% CI) P-value
Gender Female 3375 773 23 0.75(0.67–0.82) ,0.001 0.70 (0.62–0.81) ,0.001
Male 2385 721 30 Ref Ref
Age (years) #25 683 167 24 1.01 (0.84–1.26) 0.90 1.36 (1.03–1.79) 0.03
25–30 1262 329 26 1.09 (0.90–1.32) 0.37 1.31 (1.03–1.65) 0.03
31–35 1246 333 27 1.11 (0.92–1.35) 0.27 1.19 (0.94–1.50) 0.15
35–40 1071 303 28 1.18 (0.97–1.45) 0.09 1.30 (1.03–1.64) 0.03
41–45 850 209 25 1.03 (0.83–1.27) 0.76 1.00 (0.78–1.29) 0.97
46+ 648 153 24 Ref Ref
Educational Level Post-Secondary 1239 271 22 0.80 (0.65–0.99) 0.03 0.75 (0.58–0.96) 0.03
Completed Secondary 2049 564 28 1.02 (0.85–1.23) 0.82 0.97 (0.78–1.21) 0.67
Completed Primary 1263 362 29 1.07 (0.88–1.30) 0.50 1.01 (0.80–1.27) 0.93
Quranic education 260 75 29 1.02 (0.77–1.35) 0.87 1.08 (0.74–1.56) 0.70
Others 163 27 17 0.61 (0.41–0.93) 0.02 0.54 (0.33–0.89) 0.02
None or some Primary 531 143 27 Ref Ref
Marital Status Currently Married 3134 819 26 1.01 (0.92–1.12) 0.78 0.93 (0.82–1.06) 0.30
Currently Not Married 2596 666 26 Ref Ref
Employment Status Student or Unemployed 1146 269 23 0.90 (0.78–1.04) 0.17 0.99 (0.82–1.20) 0.97
Other/Retired 2224 614 28 1.04 (0.93–1.18) 0.45 1.04 (0.90–1.20) 0.53
Employed 1942 511 26 Ref Ref
Disclosure of HIV+ Status To Spouse or Family Members 4058 1000 25 0.96 (0.82–1.12) 0.57
To Others Only 240 55 23 0.89 (0.66–1.20) 0.45
To No One 733 187 26 Ref
Time to Travel to the ART .2 Hours 1196 290 24 0.90 (0.78–1.02) 0.11
Center .1–2 Hours 1533 400 26 0.97(0.86–1.10) 0.68
#1 Hour 2862 768 27 Ref
CD4 Absolute Count at .350 cells/mL
3 251 78 31 1.47 (1.15–.1.89) 0.002 1.62 (1.25–2.11) ,0.001
Initiation of ART 201–350 cells/mL
3 858 187 22 1.04 (0.87–1.25) 0.63 1.07 (0.89–1.30) 0.47
100–200 cells/mL
3 1567 329 21 Ref Ref
,100 cells/mL
3 1954 576 30 1.41 (1.23–1.61) ,0.001 1.37 (1.18–1.57) ,0.001
First Line ART Regimen ZDV+3TC+NVP or EFV 2669 630 24 0.85 (0.76–0.95) 0.004 0.76 (0.67–0.87) ,0.001
Prescribed TDF+3TC+NVP or EFV 731 196 27 0.93 (0.79–1.09) 0.37 0.83 (0.69–1.00) 0.05
d4T+3TC+NVP or EFV 2360 668 28 Ref Ref
aTotals always do not sum to 5,760 due to missing data;
bA total of 4,177 subjects included in the adjusted model; HR, hazard ratio; CI, confidence interval.
doi:10.1371/journal.pone.0010584.t002
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correlation between adherence and immunologic response report-
ed in other studies[49] coupled with limited resources for
obtaining viral load measurements, pharmacy refill data is a
convenient tool for determining whether a patient is likely to fail
therapy in the absence of viral load measurements. These
limitations may be considered significant but they do reflect the
realities of HIV treatment programs in many resource-limited
settings.
In summary, although rapid scale-up of ART in Nigeria has
been remarkable, issues such as patient retention and adherence
are likely to remain critical factors in patient-level and program-
level success. A variety of models of service delivery such as
availability of ART services at the primary health center level,
home-based care, and task-shifting are being piloted and evaluated
to enhance treatment adherence support. Our findings formed the
basis for implementing multiple pre-treatment visit preparation
that promote disclosure and active community outreaching to
support retention and adherence. Keeping patients on treatment
should be considered as important a factor as boosting the
numbers of patients initiation ART. Coupled with expansion of
treatment access points of care to communities to diminish travel
Table 3. Associations with Pharmacy Refill (Rx) ,95% Among Treatment-Naı ¨ve Adult Nigerian Patients based on GEE.
Unadjusted Adjusted
b
N
a OR (95% CI) P-value OR (95% CI) P-value
Gender Female 2743 1.05 (0.98–1.12) 0.15 0.99 (0.91–1.09) 0.87
Male 1786 Ref Ref
Age (years) #25 551 1.22 (1.07–1.38) 0.003 1.18 (0.98–1.41) 0.07
26–30 979 1.29 (1.15–1.44) ,0.0001 1.28 (1.10–1.48) 0.001
31–35 971 1.15 (1.02–1.28) 0.02 1.16 (1.00–1.34) 0.044
36–40 823 1.18 (1.04–1.32) 0.008 1.12 (0.97–1.30) 0.12
41–45 603 1.02 (0.89–1.16) 0.80 1.03 (0.88–1.21) 0.70
$46 602 Ref Ref
Educational Level Post-Secondary 1011 1.05 (0.92–1.19) 0.46 1.03 (0.88–1.21) 0.73
Completed Secondary 1588 1.03 (0.91–1.16) 0.69 1.02 (0.89–1.18) 0.75
Completed Primary 962 0.94 (0.82–1.07) 0.34 0.98 (0.84–1.14) 0.79
Quranic 205 1.40 (1.15–1.69) 0.0006 1.37 (1.01–1.84) 0.040
None or Some Primary 414 Ref Ref
Marital Status Currently Married 2454 0.96 (0.90–1.02) 0.20
Currently Not Married 2052 Ref
Disclosure of HIV+ Status To Spouse or Family Members 3228 0.85 (0.76–0.94) 0.002 0.85 (0.75–0.97) 0.01
To Others Only 193 0.94 (0.78–1.12) 0.49 0.92 (0.74–1.14) 0.45
To No One 579 Ref Ref
Employment Status Student or Unemployed 931 1.16 (1.06–1.27) 0.001 1.10 (0.98–1.24) 0.12
Other/Retired 1705 0.99 (0.91–1.07) 0.76 1.07 (0.98–1.18) 0.14
Employed 1513 Ref Ref
Time to Travel to the ART Center .2 Hours 963 1.01 (0.93–1.10) 0.80 1.11 (1.01–1.23) 0.039
.1–2 Hours 1202 0.97 (0.89–1.05) 0.39 1.07 (0.97–1.17) 0.19
#1 Hour 2223 Ref Ref
CD4 Absolute Count at Initiation of ART .350 Cells/mL
3 187 1.38 (1.18–1.62) ,0.0001 1.25 (1.05–1.49) 0.01
.200 and #350 Cells/mL
3 707 1.20 (1.08–1.32) 0.0006 1.18 (1.06–1.32) 0.003
$100 and #200 Cells/mL
3 1293 Ref Ref
,100 Cells/mL
3 1464 1.00 (0.92–1.09) 0.98 0.98 (0.89–1.08) 0.63
First Line ART Regimen Prescribed TDF+3TC+NVP or EFV 671 0.61 (0.54–0.69) ,0.0001 0.73 (0.62–0.84) ,0.0001
ZDV+3TC+NVP or EFV 2942 0.88 (0.83–0.94) ,0.0001 0.96 (0.88–1.05) 0.37
d4T+3TC+NVP or EFV 916 Ref Ref
Total Time on ART .15 and #20 months 515 1.54 (1.38–1.72) ,0.0001 1.35 (1.15–1.58) 0.0002
.12 and #15 months 880 1.33 (1.20–1.48) ,0.0001 1.20 (1.05–1.37) 0.007
.9 and #12 months 800 1.30 (1.17–1.45) ,0.0001 1.22 (1.07–1.39) 0.003
.6 and #9 months 1025 1.20 (1.08–1.34) 0.001 1.20 (1.06–1.36) 0.005
$3 and #6 months 1309 Ref Ref
aTotals do not always sum to 4,529 due to missing data;
bA total of 3,136 subjects included in the adjusted model; OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0010584.t003
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have a positive impact on adherence.
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